Literature DB >> 12211356

Immune-mediated hearing loss: basic mechanisms and options for therapy.

Allen F Ryan1, Jeffrey P Harris, Elizabeth M Keithley.   

Abstract

Immune responses are an important component of the defense of the inner ear against infection. However, immunity appears to be restricted in the labyrinth, as the inflammation associated with immune responses can damage the delicate cellular structures that mediate hearing and balance. When immunoregulation is compromised, either experimentally or through disease, immune-mediated inner ear damage and hearing loss can result. Because there are few resident leukocytes within the labyrinth, immunity and inflammation are mediated primarily by cells that enter the inner ear following the activation of post-capillary venules, which in the cochlea are the spiral modiolar veins. Activated lymphocytes are an important component of the infiltrating leukocytes, and their interactions with antigen mediate inner ear immunity. While evidence of autoimmunity specific to the inner ear is incomplete, an autoimmune origin is often suspected in idiopathic, bilateral, rapidly progressive hearing loss. Systemic immunosuppressive drugs can be effective in reversing such hearing loss, although at the cost of occasionally severe side-effects. Experimental evidence suggests that local therapy may be effective in treating this condition, if it were to target the infiltration of leukocytes into the labyrinth.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12211356     DOI: 10.1080/00016480260094965

Source DB:  PubMed          Journal:  Acta Otolaryngol Suppl        ISSN: 0365-5237


  24 in total

1.  Therapy of hearing disorders - conservative procedures.

Authors:  Stefan Plontke
Journal:  GMS Curr Top Otorhinolaryngol Head Neck Surg       Date:  2005-09-28

2.  IL-1β is overexpressed and aberrantly regulated in corticosteroid nonresponders with autoimmune inner ear disease.

Authors:  Shresh Pathak; Elliot Goldofsky; Esther X Vivas; Vincent R Bonagura; Andrea Vambutas
Journal:  J Immunol       Date:  2011-01-03       Impact factor: 5.422

Review 3.  Intratympanic steroid therapy for inner ear diseases, a review of the literature.

Authors:  M J R C Alles; M A der Gaag; R J Stokroos
Journal:  Eur Arch Otorhinolaryngol       Date:  2006-05-25       Impact factor: 2.503

Review 4.  Recent findings and emerging questions in cochlear noise injury.

Authors:  Kevin K Ohlemiller
Journal:  Hear Res       Date:  2008-08-29       Impact factor: 3.208

5.  Development of a microfluidics-based intracochlear drug delivery device.

Authors:  William F Sewell; Jeffrey T Borenstein; Zhiqiang Chen; Jason Fiering; Ophir Handzel; Maria Holmboe; Ernest S Kim; Sharon G Kujawa; Michael J McKenna; Mark M Mescher; Brian Murphy; Erin E Leary Swan; Marcello Peppi; Sarah Tao
Journal:  Audiol Neurootol       Date:  2009-11-16       Impact factor: 1.854

Review 6.  Innovative pharmaceutical approaches for the management of inner ear disorders.

Authors:  Umberto M Musazzi; Silvia Franzé; Francesco Cilurzo
Journal:  Drug Deliv Transl Res       Date:  2018-04       Impact factor: 4.617

Review 7.  MicroRNAs: effective elements in ear-related diseases and hearing loss.

Authors:  Mohammad-Reza Mahmoudian-Sani; Ameneh Mehri-Ghahfarrokhi; Fereshteh Ahmadinejad; Morteza Hashemzadeh-Chaleshtori; Massoud Saidijam; Mohammad-Saeid Jami
Journal:  Eur Arch Otorhinolaryngol       Date:  2017-02-21       Impact factor: 2.503

Review 8.  Immunosuppressive therapy for autoimmune inner ear disease.

Authors:  Maria C Buniel; Katie Geelan-Hansen; Peter C Weber; Vincent K Tuohy
Journal:  Immunotherapy       Date:  2009-05       Impact factor: 4.196

9.  Systemic immunity influences hearing preservation in cochlear implantation.

Authors:  Melanie Souter; Hayden Eastwood; Paul Marovic; Gordana Kel; Sarin Wongprasartsuk; Allen F Ryan; Stephen John O'Leary
Journal:  Otol Neurotol       Date:  2012-06       Impact factor: 2.311

Review 10.  Function of the audiovestibular system in children with systemic lupus erythematosus.

Authors:  Ghada Ibrahim Gad; Hanan Abdelateef
Journal:  Curr Allergy Asthma Rep       Date:  2014-07       Impact factor: 4.806

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.